Avista Pharma Acquires Solid Form Solutions
Avista Pharma's strengthens early phase drug development offerings with acquisition of Solid Form Solutions.
Avista Pharma Solutions expanded its solid-phase chemistry services with the acquisition of Solid Form Solutions on Jan. 23, 2018, adding solid state chemistry and crystallization development services for the pharmaceutical industry.
The company now offers a suite of drug development services ranging from analytical development to API and drug product manufacturing, according to a Jan. 23, 2018 statement announcing the completion of the acquisition.
Solid Form Solutions will continue operating in its Edinburgh, Scotland facility, providing salt screening and selection services, co-crystal and polymorph screening, crystallization development, and other analytical testing and development.
In 2017, Avista Pharma announced the expansion of analytical research and development capabilities in Durham, NC; API and drug product manufacturing capacity in Longmont, CO; and microbiology and sterility testing capabilities in Agawam, MA.
Source: Avista Pharma Solutions
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
